Prostate cancer patients see high survival rates with seed implants

	Tweet

More than ninety percent of men who receive appropriate radiation dose levels with permanent radiation seed implants to treat their prostate cancer are cured of their cancer eight years after diagnosis, according to a study released in the February 1 issue of the International Journal for Radiation Oncology*Biology*Physics, the official journal of ASTRO.

Seed implants have become a widely-accepted treatment option for early stage prostate cancer because it is very effective at curing the cancer, is minimally invasive and often spares patients from side effects of other treatments, such as impotence and incontinence. The seeds, similar in size to a grain of rice, contain a radiation dose that, once implanted, delivers concentrated radiation to the prostate, sparing surrounding organs and tissue. 

Doctors in this study evaluated the long-term results of permanent seed implants in men with early stage prostate cancer. Nearly 2,700 men were studied at 11 institutions in the United States over eight years. The radioactive seeds were administered with the aid of ultrasound-guided techniques to accurately place the seeds in the prostate gland. The patients received the seed implants as the sole treatment for prostate cancer with no additional chemotherapy or radiation therapy.

“This study is exciting because it shows that brachytherapy alone without additional surgery, radiation or drugs can be effective at curing early-stage prostate cancer,” said Michael J. Zelefsky, M.D., lead author of the study and Chief of Brachytherapy Services at Memorial Sloan-Kettering Cancer Center in New York. “These results also confirm other findings that the quality of the seed implant is a critical ingredient for achieving a better outcome.”
###

Medical centers participating in the study were Memorial Sloan-Kettering Cancer in New York, M.D. Anderson Cancer Center in Houston, New York Prostate Institute in Oceanside, N.Y., Arizona Oncology Services in Scottsdale, Ariz., Seattle Prostate Institute in Seattle, Chicago Prostate Institute in Chicago, Cleveland Clinic Foundation in Cleveland, Massachusetts General Hospital in Boston, Mayo Clinic in Rochester, Minn., University of Michigan Medical School in Ann Arbor, Mich., and Fox Chase Cancer Center in Philadelphia.

American Society for Therapeutic Radiology and Oncology

RELATED STORIES:
Scientists Link Variations in Growth-Factor Gene to Risk of Prostate Cancer   Heavy men fare poorly with prostate cancer   Men often not told of prostate cancer risks: study   Scientists Target Aggressive Prostate Cancer   Coffee may reduce risk of lethal prostate cancer in men   Innovation and current status of prostate cancer gene therapy featured in Human Gene Therapy   Researchers find prostate cancer stem cell   Obesity ups odds that prostate cancer will recur   Researchers identify promising cancer drug target in prostate tumors   Surgery Outperforms Drug Therapy in Treatment of Benign Prostatic Hyperplasia   Severe Form of “Enlarged Prostate” Disease Discovered   Chillies send prostate cancer cells on a suicidal path   High-risk prostate cancer associated with significantly lower bone mineral content loss   Genetic map of prostate cancer cracked   Waiting on prostate treatment not distressing for most   Prostate Cancer - Patterns of Progression   Prostate technique provides new insights   Soya products, beans and sunflower seeds reduce risk of contracting prostate cancer   Patients who refuse prostate cancer surgery have worse long-term survival   Excessive Multivitamin Use May Raise Risk for Prostate Cancer   Prostate cancer screen test flawed   Black men least likely to get prostate cancer screening even during peak ages of risk

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]